Berinert (C1 Esterase Inhibitor) Patent Expiration, LOE Window & CMS Spending

Berinert (C1 Esterase Inhibitor) by CSL Behring: Off-Patent Genericized (AB Competition), 0 AB generics, $49.1M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCSL Behring
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$49.1M
2024 Medicare Part D Spend$34.6M
2024 Medicaid Spend$14.6M
Reported Wholesale Price Change (CA SB 17)5 WAC filings (max 25.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for CSL Behring across sibling Meru public-data platforms.